Pharmacological management of treatment-resistant obsessive-compulsive disorder (Q37893636)

24 August 2017

1 reference

title

Pharmacological management of treatment-resistant obsessive-compulsive disorder (English)

1 reference

obsessive-compulsive disorder

24 August 2017

1 reference

0 references

3

Joseph Zohar

1 reference

24 August 2017

Anat Abudy

1

1 reference

24 August 2017

Alzbeta Juven-Wetzler

series ordinal

2

1 reference

24 August 2017

publication date

1 July 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

25

1 reference

24 August 2017

issue

7

1 reference

24 August 2017

page(s)

585-596

1 reference

The Yale-Brown Obsessive Compulsive Scale. II. Validity

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Treatment strategies for obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Treatment of severe, treatment-refractory obsessive-compulsive disorder: a study of inpatient and community treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Obsessive-compulsive and spectrum disorders in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Impact of obsessive-compulsive disorder on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Quality of life in obsessive-compulsive disorder: an evaluation of impairment and a preliminary analysis of the ameliorating effects of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Quality of life in the anxiety disorders: a meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Clinical practice. Obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Current trends in drug treatment of obsessive–compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Escitalopram in the treatment of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

High-dose escitalopram for the treatment of obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Depression, anxiety and obsessive-compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Addition of desipramine to serotonin reuptake inhibitors in treatment- resistant obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

A single-blinded case-control study of memantine in severe obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Nicotine treatment of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

D-amphetamine in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Treatment non-response in OCD: methodological issues and operational definitions

21 January 2018

2 references

https://api.crossref.org/works/10.2165/11587860-000000000-00000

21 January 2018

12 December 2020

Quetiapine Addition in Obsessive-Compulsive Disorder: Is Treatment Outcome Affected by Type and Dose of Serotonin Reuptake Inhibitors?

1 reference

https://api.crossref.org/works/10.2165/11587860-000000000-00000

Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.

21 January 2018

1 reference

12 December 2020

A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder

1 reference

12 December 2020

Differential effects of exposure and response prevention in obsessive-compulsive washers

1 reference

12 December 2020

Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.

1 reference

12 December 2020

Beyond refractory obsessions and anxiety states: toward remission.

1 reference

12 December 2020

The social costs of anxiety disorders.

1 reference

12 December 2020

Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder

1 reference

12 December 2020

High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial.

1 reference

12 December 2020

Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder.

1 reference

12 December 2020

A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder.

1 reference

12 December 2020

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder

1 reference

12 December 2020

A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.

1 reference

12 December 2020

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics

1 reference

12 December 2020

A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder

1 reference

12 December 2020

Effectiveness of exposure and ritual prevention for obsessive-compulsive disorder: Randomized compared with nonrandomized samples

1 reference

12 December 2020

Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.

1 reference

12 December 2020

The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence.

1 reference

12 December 2020

Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.

1 reference

12 December 2020

Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial

1 reference

12 December 2020

Obsessive-compulsive disorder: boundary issues

1 reference

12 December 2020

A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy

1 reference

12 December 2020

Practice guideline for the treatment of patients with obsessive-compulsive disorder

1 reference

12 December 2020

Placebo-controlled trial of fluoxetine and phenelzine for obsessive- compulsive disorder

1 reference

12 December 2020

Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.

1 reference

12 December 2020

Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study.

1 reference

12 December 2020

Acute psychostimulant challenge in primary obsessive-compulsive disorder

1 reference

12 December 2020

Use of monochlorimipramine in psychiatric patients who are resistant to other therapy

1 reference

12 December 2020

An open-label trial of St. John's Wort (Hypericum perforatum) in obsessive-compulsive disorder

1 reference

12 December 2020

Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial

1 reference

12 December 2020

Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology

1 reference

12 December 2020

New pharmacotherapeutic approaches to obsessive-compulsive disorder

1 reference

12 December 2020

10.2165/11587860-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

24 August 2017

1023967318

0 references

1 reference